Both in Pharmaceuticals
Gyre Therapeutics vs Phathom Pharmaceuticals
Over the past year GYRE returned −38.8% and PHAT returned −57.9%; their daily moves had a correlation of 0.19.
GYRE −38.8% PHAT −57.9%Growth of $1, one year, split-adjusted
| Metric | GYRE | PHAT |
|---|---|---|
| Price | $4.44 | $5.68 |
| Market cap | $470.8M | $461.7M |
| Today | 0.00% | −1.05% |
| 1 month | −37.3% | −16.2% |
| 6 months | −44.8% | −55.2% |
| Year to date | −37.1% | −65.8% |
| 1 year | −39.7% | −58.6% |
| Revenue growth (YoY) | −2.1% | +71.1% |
| Gross margin | 92.4% | 78.3% |
| Net margin | −40.1% | −16.4% |
| P/E (TTM) | — | — |
| Price / sales | 3.9× | 1.7× |
| Net cash | $74.8M | $17.6M |
| Dividend yield | — | — |
| Volatility (60d) | 88.3% | 72.0% |
| Short % of float | 11.5% | 17.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).